Pathophysiology
Gout |
Inflammatory condition. |
What makes Gout painful? |
Build up of uric acid crystals in the joints, bones, or soft tissues. Usually affects one joint at a time and is most often the metatarsal phalangeal joint (MPJ) |
What in the blood can lead to Gout? |
Elevated uric acid levels |
Hyperuricemia for males is what level? |
>7 mg/dL |
Hyperuricemia for |
>6 mg/dL |
Hyperuricemia does not always lead to... |
does not always lead to gout. |
At 37 degrees C, serum urate concentrations >7 mg/dL begin to limit... |
solubility for monosodium urate. |
Higher concentrations of serum urate will lead to more what? |
monosodium urate crystals (MSU) |
Gout is more prevalent societies with__. |
Lifestyles of overindulgence |
Uric acid is the final step in the degradation of_____ |
Purines |
The two common abnormalitites in enzymes that lead to increased uric acid |
- Increased levels of PRPP (Phsphoribosyl pyrophosphate synthetase) -Deficiency of HGPRT (HYPOxanthine-guanine phosphoribosyltransferase) |
Tophi is created by |
Uric acid binding to sodium and creating monosodium urate (msu) crystals that get deposited in tissues/joints |
Tophi is |
the build up of uric acid crystals in the synovial fluid |
Non-Modifiable Risk factors of Gout |
Age, Sex, Race, Genetic Variants |
Modifiable Risk Factors of Gout |
Obesity, HTN, CKD, Diabetes, Medications altering urate balance |
Medications that alter urate balance: |
Diuretics, Ethanol, Salicylates (<2g/day), Nicotinic Acid, Pyrazinamide, Cyclosporin |
Gout Prophylaxis
First line for Gout Prophylaxis |
NSAIDs, Colchicine |
Colchicine |
0.6 mg PO daily or BID (QD>BID) |
NSAID |
Naproxen is an example (250 mg PO BID). May use a PPI if NSAID prolonged or increased GI bleeding risk. |
Alternative/First line contraindicated Prophylaxis dosing |
Low dose corticosteroids (like prednisone 10 mg/day) |
Duration of Propphylaxis without tophi |
3-6 months |
Duration of Prophylaxis with >1 tophi or radiographic evidence |
6-12 months |
Uricosuric
2nd line Therapy for Gout Management |
Probenecid |
Rarely used monotherapy... |
but can be XOI is contraindicated or ineffective |
Probenecid initial dosing |
250 mg PO BID x1 week |
Probenecid maintenance dosing |
500 mg PO BID |
Mainly for patients that... |
underexcrete uric acid |
MOA |
Competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby promoting its excretion and reducing serum uric acid levels |
Works where? |
RENALLY |
Contraindicated |
Nephrolithiasis, moderate-severe renal impairment (CKD 3) |
Effect of Salicylates on Probenecid |
may impact the concentrations |
Recombinant Uricase
Pegloticase |
8 mg IV infusion (over 120min) q2weeks |
MOA |
Pegylated recombinant form of urate-oxidase enzyme, also known as uricase; which converts uric acid to allantoin (an inactive and water soluble metabolite of uric acid) |
ethicacy: |
4-6 months |
MONOTHERAPY |
Can only be used as monotherapy |
Used for |
Refractory gout when failed conventional therapies. |
Produced from modified strain of |
E. coli (Escherichia coli) |
Start prophylactic therapy |
1 week PRIOR to initiation (high risk of flares) |
Duration of prophylaxis while on Pegloticas |
6 months |
Requires... |
Pre-treatment with antihistamines and corticosteroids to mitigate infusion reaction |
Immunogenicity |
develops antibodies against itself |
Discontinue therapy: |
serum urate >6 mg/dL on more than one clinic visi |
Contraindicated: |
G6PD-deficiency |
G6PD-deficiency |
Increase risk of Hemolysis and methemoglobinemia |
|
|
Diagnosis, Signs, Symptoms, Classification
Diagnosis of Gout |
Symptoms are used for diagnosis |
Signs and Symptoms of Gout |
Intense pain, Erythema, warmth, Fever, Tophi, Inflammation of Joint |
Where can inflammation of the joint be in Gout? |
Toes, Knees, Fingers, Elbows, Ankles |
Uric Acid Levels |
High uric acid levels do NOT always mean Gout! |
Leukocytosis in Gout |
MSU crystals induce inflammation and can INCREASE white blood cell count |
Diagnostic Testing for Gout |
Arthrocentesis and Radiography |
Arthrocentsis |
Removal of synovial fluid from the affected joint, microscopic examination, can give a definitive diagnosis of gout. |
Radiography |
X-ray that can be used for more advanced gout, will be *unremarkable for first acute gout attacks, can help rule out other causes of arthritis. |
Conditions that precipitate Gout Attack |
Most can't identify a trigger. Dehydration, Stress, excessive alcohol intake, excessive intake of purine-rich foods, increased physical activity, uric acid lowering agents, medications that increase uric acid levels |
What are the 4 Gout Classifications |
Asymptomatic, Acute Gouty Arthritis, Intercritical Gout, Chronic recurrent Gout |
Asymptomatic |
Hyperuricemia |
Intercritical Gout |
Intervals between attacks |
Severity of Chronic Tophaceous Gouty Arthritis (CTGA) |
Mild, Moderate, Severe |
CTGA Mild |
One joint, stable disease |
CTGA Moderate |
2-4 joints, stable disease |
CTGA Severe |
4+ OR Unstable, complicated, severe articular tophi |
Large Joints: |
Knee, ankle, wrist, elbow, hip, shoulder |
Medium Joints: |
Ankle, Wrist, Elbow |
Small Joints: |
Interphalangeal |
Xanthine Oxidase Inhibitors (XOI)
What are the Two XOI for Gout? |
Allopurinol, Febuxostat |
Allopurinol Initial dose |
100 mg PO daily |
Allopurinol Maintenance dosing |
100-800 mg daily (average is 300 mg/day) |
Allopurinol Renal adjustment |
50 mg/day for CKD stage 4+ |
Febuxostat initial dose |
40 mg PO daily |
Febuxostat Maintenance dosing |
40-80 mg daily |
First line agent for |
Chronic management of gout |
Contraindications |
CVD history or recent CV event |
Genotype contraindication |
HLC-B*5801 haplotype |
Genotype is conditionally recommended for what race? |
Southeast Asian descent, African Americans |
XOI MOA |
Inhibits xanthine oxidase, an enzyme responsible for the conversion of hypoxanthine to xanthine to development of uric acid. Acts on purine metabolism, thereby reducing uric acid production without disrupting biosynthesis of vital purines |
Black Box Warning |
Febuxostat |
|
|
Gout Management
Non-Pharmacological |
Dietary Modifications, Promote Weight Loss, Adjuvant ice therapy, Avoid heat |
Pharmacotherapy of Acute Gout |
Terminate acute attacks, Prevent Recurrent Attacks of gouty arthritis, Prevent complications associated with deposition of urate crystals in tissues, Prevent/reverse comorbidities associated with gout (Obesity, HTN) |
Dietary Modifications for Gout |
Limit: Purine (meats, seafood), alcohol (beer, fortified wines/liquours), high-fructose corn syrup, maintain adequate hydration |
Acute Gout Treatment |
NSAIDS, Corticosteroids, Colchicine |
NSAIDS can be initiated when for a Acute attack? |
24-48 hours |
Celecoxib should be avoided if significant history of what? |
CAD |
NSAIDs with Acute Gout Attack FDA indication: |
Indomethacin, Naproxen, Sulindac |
NSAIDs are contraindicated for |
Decompensated heart failure. |
NSAIDs MOA |
Inhibit prostaglandins for anti-inflammatory, analgesic and antipyretic effects via inhibition of cycloxygenase 1 and 2 enzymes |
Corticosteroids can be initiated when for an acute gout attack? |
24-48 hours |
Corticosteroids for Acute Gout attack: |
Prednisone, Methylprednisolone, Triamcinolone, ACTH |
ACR guidelines recommend this as an option for acute gout flare: |
Corticosteroids |
Corticotropin’s anti- inflammatory properties work through: |
melanocortin type-3 receptor |
Corticosteroids are contraindicated when? |
Active systemic infections (can worsen them), IA injections if septic arthritis, long term use decreases amoutn of physiological steroids so there can be rebound which is why we taper |
Adverse event of corticosteroid use: |
HPA axis suppression |
When can Colchicine be initiated for Acute Gout attack? |
12-24 hours of symptom onset. if >36 hours, consider alternative therapies |
Colchicine for acute gout attack initial dosing: |
Day 1: 1.2 mg PO once, then 0.6 mg PO 1-6 hour later |
Colchicine for acute gout attack mainenance dosing: (Day 2) |
12 hours after Day one, 0.6 mg PO daily or BID |
Colchicine MOA |
Decreases inflammation during gout flare by decreasing activation, degranulation and migration of neutrophils through inhibiting betatubulin polymerization into microtubules |
Colchicine is Contraindicated when: |
Blood dyscrasias, severe renal disease (CrCl <10 ml/min) |
If gout is seen on an x-ray, it's immediately classified as |
Severe |
Initiate Monotherapy |
Mild/Moderate Pain intensity |
Initiate Combination Therapy |
Severe, X-ray |
Combination therapy includes |
Colchicine + NSAID, Colchicine + Oral Corticosteroid, NSAID + IA injection, Colchicine + IA, Oral Corticosteroid + IA |
Goal Serum Urate level to maintain |
<6 mg/dL |
When using a ULT, what should also be used? |
Anti-inflammatory to overlap |
High level of evidence/Strong recommendation for Initiation of ULT |
1 or more subcutaneous tophi, evidence of radiographic damage from gout, >2 gout flares per year |
Moderate Evidence, Conditional recommendation |
ULT is recommended for patients who have previously experienced >1 flare but have infrequent flares (<2 per year) |
ULT options for Gout |
Xanthine Oxidase Inhibitors (XOI), Recombinant Uricase, Probenecid |
Fenofibrate |
Increase clearance of hypoxanthine and xanthine. Consider if concomitant Hypertriglyceridemia |
Losartan |
Inhibits tubular reabsorption of uric acid and increases excretion. Alkalinizes urine to reduce risk of calculi |
Asymptomatic Hyperuricemia treatment |
No pharmacotherapy required , Target lifestyle modifications |
|